Trazodone and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Trazodone (a serotonin antagonist and reuptake inhibitor, or SARI, sold generically and formerly as Desyrel) and tadalafil (a PDE5 inhibitor, sold as Cialis and in a lower-dose daily formulation, and also marketed as Adcirca for pulmonary arterial hypertension) are not a contraindicated pair. Both drugs lower blood pressure through separate mechanisms, and the combined effect can produce orthostatic dizziness or, rarely, fainting. This is a moderate, manageable interaction in most adults, not an absolute barrier to use, but it requires a deliberate starting dose and a follow-up blood pressure check rather than routine co-prescribing without comment.

This article covers oral tadalafil (Cialis/Adcirca) taken with oral trazodone. It does not address trazodone combined with nitrates through tadalafil (an absolute, separate contraindication) or combinations involving other PDE5 inhibitors, which share the same general mechanism but differ in half-life.

The core answer

Trazodone's alpha-1 adrenergic blockade and tadalafil's nitric oxide-mediated vasodilation act on different points in the vascular pathway but both reduce peripheral resistance, so their blood-pressure-lowering effects can add together rather than cancel out. This additive pharmacodynamic effect, not a pharmacokinetic drug-level interaction, is the primary safety concern; both the trazodone label and the tadalafil label warn separately about combining either drug with other agents that lower blood pressure. The practical response is to start tadalafil at its lowest labeled dose when a patient is already on trazodone, and to check seated and standing blood pressure within the first couple of weeks.

Why the combination raises a flag

Trazodone produces meaningful alpha-1 adrenergic blockade, which is why orthostatic hypotension and syncope appear as warnings in its FDA label, with the label noting increased risk when trazodone is combined with antihypertensives or other blood-pressure-lowering drugs. Tadalafil relaxes vascular smooth muscle through the nitric oxide/cGMP pathway, and its label warns that PDE5 inhibitors add to the blood-pressure-lowering effect of alpha-blockers and other vasodilators, which is the same pharmacologic family of effect trazodone produces through a different receptor.

Neither warning was written with the other drug specifically in mind, but the mechanisms overlap enough that the general caution in each label applies to this pairing. This is not a drug combination that has been withdrawn or restricted; it is one that calls for the same caution the labels already describe for "other vasodilating drugs."

Is there a pharmacokinetic interaction, or is this purely additive effect?

Trazodone is metabolized in part by CYP3A4 to an active metabolite, and tadalafil is also cleared through CYP3A4. In principle, two CYP3A4 substrates competing for the same enzyme could raise each other's blood levels, but neither drug is considered a strong CYP3A4 inhibitor or inducer at typical doses, so any drug-level shift from this competition would be expected to be small. We could not verify a specific published pharmacokinetic study quantifying trazodone's effect on tadalafil blood levels for this article, and that claim should be checked against the primary literature before it is repeated as an established finding.

What matters more clinically is that tadalafil has a long elimination half-life, on the order of 17 hours, which is well documented in its FDA label. That means a dose taken in the afternoon can still be present in the bloodstream the next morning when a bedtime dose of trazodone is also active. For patients using low-dose daily tadalafil (2.5 mg or 5 mg), steady-state drug levels are present around the clock, so separating the timing of the two drugs by a few hours does little to reduce overlapping exposure. For as-needed tadalafil, taking it several hours apart from trazodone reduces the chance both drugs are at peak effect simultaneously, though it does not eliminate overlap entirely.

How much does blood pressure actually drop?

The tadalafil label reports that the drug produces a small additional reduction in blood pressure beyond placebo in healthy volunteers, and that this effect is more pronounced when tadalafil is combined with an alpha-blocker; the label recommends starting at the lowest tadalafil dose in patients already taking an alpha-blocking medication. Trazodone's own label lists orthostatic hypotension as a common adverse effect, though we did not have a source we could verify for this draft that gives a precise incidence percentage specific to trazodone alone, and any number cited for that rate should be checked against the current label or a verified clinical trial report before being used as a hard figure in patient counseling material.

What is reasonably well established, without needing a precise number, is the direction and rough magnitude: patients who are more sensitive to blood pressure drops from either drug alone (older adults, those already on antihypertensives, anyone volume-depleted) are more likely to notice symptoms when the two are combined. This is a case where the qualitative direction of risk is solid even though a specific combined-incidence figure for this exact pairing does not appear to exist in the published literature.

Risk factors that make the interaction more likely to cause symptoms

• Age over 65. Baroreceptor reflexes that normally compensate for a blood pressure drop on standing become less responsive with age.
• Other blood-pressure-lowering drugs. Adding an ACE inhibitor, ARB, diuretic, or alpha-blocker on top of trazodone and tadalafil creates a three- or four-way additive stack.
• Volume depletion. Dehydration, heat exposure, or alcohol use reduces circulating blood volume and makes orthostatic symptoms more likely.
• Higher trazodone doses. Alpha-1 blockade is dose-related; doses above the range typically used for insomnia (which is often well below the antidepressant dose range) carry more of this effect.
• Reduced kidney function. Tadalafil clearance decreases as renal function declines, which the FDA label addresses with specific dose-adjustment guidance for patients with reduced creatinine clearance.

Priapism: a separate, rare risk shared by both drugs

Trazodone carries an FDA label warning for priapism, including prolonged erections that have required surgical intervention in reported cases. Tadalafil and other PDE5 inhibitors also carry a priapism warning in their labeling, independent of trazodone. We removed a specific incidence ratio that appeared in an earlier draft of this article because we could not verify the source behind it; readers and prescribers should check the current trazodone label and current epidemiologic literature directly if a precise incidence figure is needed for clinical decision-making, rather than relying on a number repeated without a checkable source.

The mechanisms differ: trazodone's association with priapism is thought to involve alpha-adrenergic blockade in the corpus cavernosum, which can impair the normal detumescence response, while tadalafil promotes erection through PDE5 inhibition and increased cGMP-mediated smooth muscle relaxation. Whether combining the two meaningfully increases priapism risk above either drug alone has not been established in a published case series that we could locate. This is a plausible-but-unproven concern, not a documented one, and it does not change the advice that anyone taking either or both drugs should treat an erection lasting more than four hours as a medical emergency.

Evidence-status assessment: trazodone plus tadalafil

Practical dosing and monitoring approach

If tadalafil is being started in a patient already stabilized on trazodone, the tadalafil label's general caution around alpha-blocking drugs supports beginning at the lowest available dose (the low end of the daily-use range, or the lowest as-needed dose) rather than a higher starting dose, with escalation considered only after tolerability is confirmed. If trazodone is being started in a patient already on tadalafil, a low starting trazodone dose with slow titration and bedtime administration is a reasonable, conservative approach, since sedative and hypotensive effects are most pronounced in the hours after dosing, an approach discussed further in this resource on dosing trazodone in children for younger patients.

A simple monitoring sequence:

1. Before starting the second drug: check seated and standing blood pressure. A systolic drop greater than 20 mmHg or diastolic drop greater than 10 mmHg on standing indicates impaired vascular compensation already present, independent of either drug, and deserves attention before adding a second vasodilating medication.
2. Within one to two weeks: repeat orthostatic vitals and ask specifically about dizziness on standing, lightheadedness, or near-fainting, since these symptoms often precede a full fainting episode.
3. At four to six weeks: if the patient is asymptomatic and vitals are stable, routine follow-up is reasonable.
4. Ongoing: advise rising slowly from sitting or lying positions, adequate hydration, and caution with alcohol, which adds a third vasodilatory mechanism through direct smooth muscle relaxation. General cardiovascular guidance on alcohol's blood-pressure effects is available from the National Institute on Alcohol Abuse and Alcoholism.

When the combination should be avoided or reconsidered

• Nitrates. Anyone taking nitroglycerin or another nitrate must not take tadalafil at all. This is an absolute contraindication in the tadalafil label and applies regardless of trazodone use.
• Low baseline blood pressure. The tadalafil label advises against use in patients with a resting systolic blood pressure below 90 mmHg.
• History of priapism from any cause. Given that both drugs carry independent priapism warnings, a prior priapism episode is a reason to involve a urologist before combining them.
• Potent CYP3A4 inhibitors. Drugs such as ritonavir, ketoconazole, itraconazole, or clarithromycin can raise tadalafil exposure, and the tadalafil label specifies a reduced maximum dose and dosing interval in that setting; trazodone levels may also be affected by strong CYP3A4 inhibition, though the trazodone label should be checked directly for current guidance on this point.

Alternatives worth discussing with a prescriber

If the interaction risk seems too high for a particular patient, options exist on both sides. Antidepressants with less alpha-1 blocking activity, such as SSRIs or SNRIs, produce less orthostatic hypotension than trazodone in general clinical experience, though switching medications for sleep or mood has its own tradeoffs that should be weighed with a treating clinician rather than decided from this article alone. Shorter-acting PDE5 inhibitors have shorter half-lives than tadalafil, which can make timing separation from trazodone more practical, at the cost of needing more precise timing relative to sexual activity. Non-oral options for erectile dysfunction, including vacuum erection devices and intracavernosal or intraurethral alprostadil, bypass systemic vasodilation entirely and remove the blood-pressure interaction, though they carry their own risks and are generally considered after oral therapy has been tried or ruled out.

What this means for patients

Taking trazodone and tadalafil together is common and manageable for many people, provided the combination is started at a conservative tadalafil dose with a blood pressure check planned within the first couple of weeks. Report dizziness on standing, lightheadedness, fainting, or an erection lasting more than four hours to a prescriber promptly; the last of these is a reason to seek emergency care rather than wait for a scheduled appointment. This article is general information, not an individualized dosing recommendation, and does not replace a conversation with the prescriber who knows a patient's full medication list, kidney function, and blood pressure history.

Evidence boundary

Established: both drugs lower blood pressure through independent mechanisms and both carry FDA label warnings about combining with other vasodilating or hypotensive drugs; both carry independent priapism warnings; tadalafil has a long half-life that limits how much timing separation can reduce overlapping exposure.

Plausible but unproven: that combining the two meaningfully increases priapism risk beyond either drug alone; that CYP3A4 competition between the two drugs produces a clinically meaningful rise in either drug's blood level.

Not established from the sources available for this article: a specific combined incidence rate for orthostatic hypotension or priapism when the two drugs are used together. Any number a reader encounters elsewhere for these combined rates should be traced back to a specific, checkable study before it is used in clinical counseling.